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Abstract: Background: Medulloblastoma in adult patients is rare, with 0.6 cases per million.
Prognosis depends on clinical factors and medulloblastoma entity. No prospective data
on the feasibility of radio-chemotherapy exist. The German Neuro-Oncology Working
Group (NOA) performed a prospective descriptive multicenter single-arm Phase II trial
to evaluate feasibility and toxicity of radio-polychemotherapy.
Methods: The NOA-07 trial combined cranio-spinal irradiation with vincristine, followed
by eight cycles of cisplatin, lomustine and vincristine. Adverse events, imaging and
progression patterns, histological and genetic markers, health-related quality of life
(HRQoL) and cognition were evaluated. Primary endpoint was the rate of toxicity-
related treatment terminations after four chemotherapy cycles, and the toxicity profile.
The feasibility goal was reached if at least 45% of patients received at least 4 cycles of
maintenance chemotherapy.
Results: Thirty patients were evaluable. Each 50% percent showed classic and
desmoplastic-nodular histology. Sixty-seven percent were classified into the sonic
hedgehog (SHH) subgroup without TP53 alterations, 13% in wingless (WNT), and 17%
in Non-WNT/Non-SHH. Four cycles of chemotherapy were feasible in the majority
(n=21; 70.0%). Hematological side effects and polyneuropathy were prevalent
toxicities. During the active treatment period, HRQoL and verbal fluency improved
significantly. The 3-year event-free survival rate (EFS) was 66.6% at the time of
databank lock.
Conclusions: Radio-polychemotherapy did lead to considerable toxicity and a high
amount of dose reductions throughout the first four chemotherapy cycles that may
affect efficacy. Thus, we propose frequent patient surveillance using this regimen.
Modifications of the regimen may increase feasibility of radio-polychemotherapy of
adult patients with medulloblastoma.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
  
 
 
Hausadresse 
Universitätsklinikum Regensburg 
Franz-Josef-Strauß-Allee 11 
93053 Regensburg 
 
 
ÖPNV: RVV Linien 6 und 19 
Telefon: 
0941 / 941-8083 
Telefax: 
0941 / 941-63013 
 
Email: 
peter.hau@klinik.uni-regensburg.de 
Universitätsklinikum Regensburg 
Anstalt des öffentlichen Rechts 
Vorstand: 
Ärztlicher Direktor: Prof. Dr. Oliver Kölbl (Vorsitzender) 
Kaufmännischer Direktor: Dipl.-Kfm. Klaus Fischer 
Pflegedirektor: Alfred Stockinger 
Dekan der Fakultät für Medizin: Prof. Dr. Dr. Torsten E. Reichert 
 
 
 
 
 
Universitätsklinikum Regensburg, 93042 Regensburg 
 
 
Aktenzeichen Unser Zeichen 
 
Bearbeiter 
P. Hau 
Telefon 
09 41 941-8083 
Regensburg, 
18.07.2017 
     
Second Re-submission with major revisions - Ms. No. N-O-D-17-00180R1 
 
Dear Prof. Wen, 
many thanks for the opportunity to, for the second time, re-submit our above mentioned manuscript to Neuro-
Oncology with major revisions. 
Below, you will find our point-to-point answer to all reviewer comments. Please be aware that there are two 
open questions where we will need the feedback of the acting editor and the reviewer, respectively. 
We declare that our manuscript, or any part of it, has not been previously published or submitted concurrently 
to any other journal, and that all co-authors have read and approved the revised version of the manuscript. We 
further declare that we agree to pay for full color reproduction. 
We hope that the revisions will now qualify the manuscript for publication in Neuro-Oncology. We will however 
be happy to address further questions, if indicated. 
With best regards, 
 
Peter Hau, MD 
 
To  
Prof. P. Wen 
Editor-in-Chief 
 
Neuro-Oncology 
 
Wilhelm Sander-Therapieeinheit NeuroOnkologie 
im Zentrum für Hirntumoren (ZHT) 
(Leiter: Prof. Dr. P. Hau) 
Klinik und Poliklinik für Neurochirurgie 
(Direktor: Prof. Dr. A. Brawanski) 
Klinik und Poliklinik für Strahlentherapie 
(Direktor: Prof. Dr. O. Kölbl) 
Klinik und Poliklinik für Neurologie 
(Komm. Direktor: Prof. Dr. F. Schlachetzki) 
Abteilung für Neuropathologie 
(Leiter: Prof. Dr. M. J. Riemenschneider) 
 
Cover Letter
  
 
 
Hausadresse 
Universitätsklinikum Regensburg 
Franz-Josef-Strauß-Allee 11 
93053 Regensburg 
 
 
ÖPNV: RVV Linien 6 und 19 
Telefon: 
0941 / 941-8083 
Telefax: 
0941 / 941-63013 
 
Email: 
peter.hau@klinik.uni-regensburg.de 
Universitätsklinikum Regensburg 
Anstalt des öffentlichen Rechts 
Vorstand: 
Ärztlicher Direktor: Prof. Dr. Oliver Kölbl (Vorsitzender) 
Kaufmännischer Direktor: Dipl.-Kfm. Klaus Fischer 
Pflegedirektor: Alfred Stockinger 
Dekan der Fakultät für Medizin: Prof. Dr. Dr. Torsten E. Reichert 
 
 
 
 
 
Universitätsklinikum Regensburg, 93042 Regensburg 
 
 
Aktenzeichen Unser Zeichen 
 
Bearbeiter 
P. Hau 
Telefon 
09 41 941-8083 
Regensburg, 
18.07.2017 
     
Second Re-submission with major revisions - Ms. No. N-O-D-17-00180, N-O-D-17-00180R1 
 
With respect to reviewer #2, we made the following changes:  
 
”The authors have adequately responded to all of the reviewers' comments and critiques, and included 
appropriate modifications within their manuscript.“ 
Answer: Many thanks for this positive and supportive statement. 
 
“There are a few minor errors in the Tables which need amending: (1) Table 1 - the KPS ratings appear to be 
incorrectly labeled; there are gaps between the ratings. (2) Table 2 - M2/3 patients number 9, while Table 3 
indicates 10 (does the tenth include a single patient both M2 and M3?) this discrepancy needs clarification. (3) 
Table 3 - resection is described as "not applicable" -surely the authors mean "not available"? 
Answer: we carefully reviewed these statements. Concerning error (1), the ratings were KPS 100, n=8 (26,7%), 
KPS 90, n=15 (50,0%), KPS 80, n=2 (6,7%), KPS 70, n=3 (10,0%), KPS 60, n=1 (3,3%), KPS 50, n=1 (3,3%), KPS 40-
0, n=0 (0.0%) in more detail. We revised table 1 accordingly. Concerning error 2, we listed n=10 patients with 
M2 or M3-disease in table 2. Therefore, we were not able to detect a discrepancy in between data. If we 
should have overlooked the point the reviewer wanted to make, we would ask the reviewer to indicate the 
problem in more problem. Concerning error 3, we thank the reviewer for this comment and corrected the 
wording in “data not available”. 
 
To  
Prof. P. Wen 
Editor-in-Chief 
 
Neuro-Oncology 
 
Wilhelm Sander-Therapieeinheit NeuroOnkologie 
im Zentrum für Hirntumoren (ZHT) 
(Leiter: Prof. Dr. P. Hau) 
Klinik und Poliklinik für Neurochirurgie 
(Direktor: Prof. Dr. A. Brawanski) 
Klinik und Poliklinik für Strahlentherapie 
(Direktor: Prof. Dr. O. Kölbl) 
Klinik und Poliklinik für Neurologie 
(Komm. Direktor: Prof. Dr. F. Schlachetzki) 
Abteilung für Neuropathologie 
(Leiter: Prof. Dr. M. J. Riemenschneider) 
 
Response to Reviewers
  
 
 
Hausadresse 
Universitätsklinikum Regensburg 
Franz-Josef-Strauß-Allee 11 
93053 Regensburg 
 
 
ÖPNV: RVV Linien 6 und 19 
Telefon: 
0941 / 941-8083 
Telefax: 
0941 / 941-63013 
 
Email: 
peter.hau@klinik.uni-regensburg.de 
Universitätsklinikum Regensburg 
Anstalt des öffentlichen Rechts 
Vorstand: 
Ärztlicher Direktor: Prof. Dr. Oliver Kölbl (Vorsitzender) 
Kaufmännischer Direktor: Dipl.-Kfm. Klaus Fischer 
Pflegedirektor: Alfred Stockinger 
Dekan der Fakultät für Medizin: Prof. Dr. Dr. Torsten E. Reichert 
 
With respect to reviewer #3, we made the following changes:  
 
”The manuscript by Dagmar Beier and Colleagues has been extensively reviewed by the authors following the 
suggestions of the reviewers.” 
Answer: We thank the reviewer for this positive comment. 
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at "the minimal number of patients required" but the decided arbitrary that the number of patients was 30, 
without any statistical plan. To demonstrate the importance of a statistical plan that takes into account factors 
such as H0, H1, alpha, beta, drop-out rate, etc. Authors found a high level of attrition, in a small cohort of 
patients. Thus, despite this study is of interest, the results are strongly limited and potentially biased. Authors 
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prospective “descriptive" study, as they mentioned in their answer.” 
Answer: The goal of this study was to evaluate, whether the addition of cytotoxic agents to the standard 
treatment of adult medulloblastoma is feasible without unacceptable toxicity in a prespecified number of 
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design, focusing on the rate of toxicity-related treatment terminations after 4 cycles of adjuvant 
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terminations. Conceivably, this could be formulated as HO/H1 hypothesis, i.e. H0 would indicate that 60% or 
more patients show excessive toxicity leading to termination of cytotoxic treatment, which would indicate that 
the primary endpoint has not met and this treatment is not feasible. This methodology is widely accepted and 
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was not described in the prospective statistical plan of the study. However, if recommended by the reviewer, 
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feasible” in the methods section. 
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Answer: We thank the reviewer you for this helpful comment, since the wording of this sentence is in fact 
unclear. In this study, the primary endpoint was defined by a maximal rate of toxicity related treatment 
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the paper. 
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Abstract 
 
Background: Medulloblastoma in adult patients is rare, with 0.6 cases per million. 
Prognosis depends on clinical factors and medulloblastoma entity. No prospective data on the 
feasibility of radio-chemotherapy exist. The German Neuro-Oncology Working Group (NOA) 
performed a prospective descriptive multicenter single-arm Phase II trial to evaluate 
feasibility and toxicity of radio-polychemotherapy.  
Methods: The NOA-07 trial combined cranio-spinal irradiation with vincristine, 
followed by eight cycles of cisplatin, lomustine and vincristine. Adverse events, imaging and 
progression patterns, histological and genetic markers, health-related quality of life (HRQoL) 
and cognition were evaluated. Primary endpoint was the rate of toxicity-related treatment 
terminations after four chemotherapy cycles, and the toxicity profile. The feasibility goal was 
reached if at least 45% of patients received at least 4 cycles of maintenance chemotherapy. 
Results: Thirty patients were evaluable. Each 50% percent showed classic and 
desmoplastic-nodular histology. Sixty-seven percent were classified into the sonic hedgehog 
(SHH) subgroup without TP53 alterations, 13% in wingless (WNT), and 17% in Non-
WNT/Non-SHH. Four cycles of chemotherapy were feasible in the majority (n=21; 70.0%). 
Hematological side effects and polyneuropathy were prevalent toxicities. During the active 
treatment period, HRQoL and verbal fluency improved significantly. The 3-year event-free 
survival rate (EFS) was 66.6% at the time of databank lock. 
Conclusions: Radio-polychemotherapy did lead to considerable toxicity and a high 
amount of dose reductions throughout the first four chemotherapy cycles that may affect 
efficacy. Thus, we propose frequent patient surveillance using this regimen. Modifications of 
the regimen may increase feasibility of radio-polychemotherapy of adult patients with 
medulloblastoma. 
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Importance of the study: 
NOA-07 showed that combined radio-chemotherapy followed by maintenance chemotherapy 
with cisplatin, lomustine, and vincristine is more toxic in adults than in children. This 
prospective descriptive trial constitutes a unique dataset that perpetuates the development of 
effective treatments in this curable population. The results have potential to influence or even 
change clinical practice. The NOA-07 protocol can be translated to the recommendation that 
adults with medulloblastoma should be treated with attenuated radio-polychemotherapy 
regimen that consider the decreased feasibility of radio-polychemotherapy in adults in 
comparison to children. In addition, an attenuated NOA-07 regimen may serve as a basis for 
the standard arm in a subsequent trial. Current knowledge makes it likely that such a trial will 
ask a molecular question in its experimental arm and will lead into a molecularly stratified 
approach for adults with medulloblastoma.
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Introduction 
 
Medulloblastoma is rare in adults. About 70% of cases occur in patients younger than 
15 years 1. The US SEER database reports 0.6 cases per million in adults per year 2. Five-year 
overall survival depends on clinical prognostic factors 3, and on histological entity and genetic 
subgroup 4, and reaches 40-90%. Long-term sequelae interfere with functioning in daily life 5. 
Four genetic subgroups (WNT, SHH, Group 3 and Group 4) defined by expression 
patterns and epigenetic signatures allow a reliable prognostication 6. The WHO classification 
(2016, 7) developed this further to a combination of histological criteria with classic (CMB; 
60-70% in adults), desmoplastic/nodular (DNMB; 25-40%), extensive nodular (MBEN; <5%) 
and large cell/anaplastic (LCA, 10-25%) entities and genetically defined groups. These 
consist of WNT-activated, SHH-activated and TP53 wildtype, SHH-activated and TP53 
altered, and Non-WNT/Non-SHH (Group 3 and 4). Patients with MYC/MYCN-amplification 
6,8 and p53 mutation 9 have an inferior prognosis. In adults, group 3 does not exist. 
In children, the introduction of chemotherapy combined with cranio-spinal 
radiotherapy improved survival 10-12, however, associated with significant unwanted effects 13. 
The same regimen was retrospectively evaluated in a non-randomized adult sub-cohort 14. 
Radio-chemotherapy compared to radiotherapy alone improved event-free survival (EFS) (4-
year EFS, 74% v. 47%; p=0.027) and overall survival (OS) (4-year-OS, 94% vs. 81%; 
p=0.035). Retrospective data and small prospective trials also suggested an impact of 
chemotherapy in adult patients 15-17. 
NOA-07 prospectively evaluated toxicity-related treatment terminations after 4 cycles 
of adjuvant chemotherapy, and the toxicity profile in the first-line treatment of adult patients 
with medulloblastoma. Results of the active treatment period are presented here. 
 
Material and Methods 
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Treatment and ethics 
NOA-07 enrolled patients at 15 sites in Germany. The trial was approved by the Ethics 
Committee (EC) of the University of Regensburg, Germany (08-112-0058; substantial 
amendment of July 01, 2016). The trial was registered at ClinicalTrials.gov (NCT01614132). 
All patients with age above 21 and Chang stage T1-4 and M0 or M1 as diagnosed 
locally at the trial sites were included. Treatment consisted of photon cranio-spinal irradiation 
(1.6 Gy/35.2 Gy, posterior fossa boost 1.8 Gy/55 Gy) in combination with vincristine (1.5 
mg/m2 weekly, cap at 2.0 mg), followed by a maximum of eight six-weekly cycles of 
cisplatin (70.0 mg/m2, day 1), lomustine (75.0 mg/m2, day 1) and vincristine (1.5 g/m2, cap at 
2.0 mg, days 1, 8, 15). Treatment per protocol was at least one cycle of adjuvant 
chemotherapy (Suppl. Figure 1).  
 
Imaging (MRI) classification 
Cranio-spinal imaging patterns (MRI with T1-weighted (w) images, T1-w post 
gadolinium-containing contrast agent (Gd), T2-w, FLAIR) were evaluated prospectively. 
Inclusion was based on the local (neuro)radiology report. All imaging was reviewed for 
localization, extent of resection, and progression 18.  
Contrast enhancing and non-enhancing tumor volume was calculated from voxel size 
x3 multiplied with the number of target voxels using the IntelliSpace Portal® (Philips 
Healthcare). Extent of resection was evaluated for the enhancing tumor volume on early 
postsurgical MRI (24 to 72 h post-operative). Tumor progression was assessed on follow-up 
cranio-spinal MRIs after radiotherapy, before starting adjuvant chemotherapy and in 12-
weekly time intervals over three years, and six-monthly intervals thereafter.  
 
Chang classification 
N-O-D-17-00180R1 
 
 9 
Despite the fact that the Chang 3 classification was initially based on surgical reports 
and CT scans, and that it´s prognostic value is doubtable, patients were classified according to 
Chang using MRI (condensed T1-w plus gadolinium and T2-w) criteria and results from 
lumbar punctures, with the aim to morphologically describe the study population.  
 
Histological and molecular classification and CSF assessment 
All specimens were diagnosed locally and referenced by at least two experienced 
neuropathologists 19. After introduction of 2016 WHO classification amendment 7, all 
specimens were re-evaluated and an integrated diagnosis was reported.  
Immunohistochemistry was performed as described 20. Genetic entities were defined 
using immunohistochemistry with antibodies against ß-Catenin, Yap1, p75-NGFR, Otx2 and 
p53. DNA was extracted, and direct sequencing (Sanger) of exon 3 of CTNNB1 was 
performed 21. Genome-wide copy number estimation and analysis of allelic distribution was 
performed by molecular inversion profiling (MIP) 22 and analyzed by Nexus Copy Number 
7.0 Discovery Edition software (BioDiscovery, El Segundo, CA, U.S.A.). If minimal DNA 
was available, a multiplex ligation-dependent probe amplification (MLPA) was done 23.  
Global DNA methylation profiling using the Illumina Human Methylation 450 Bead 
Chip array was performed. Medulloblastoma subgrouping were done as described 20,24. 
Genome-wide copy number profiles were generated using the ‘conumee’ package 
(https://www.bioconductor.org/packages/release/bioc/html/conumee.html) in the R 
programming environment. 
As meningeosis in adults with medulloblastoma is not well described, CSF punctures 
were done in all patients at the time of diagnosis and recommended every 3 months thereafter 
or if clinical symptoms occurred. CSF was referenced centrally.  
 
Feasibility and toxicity 
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Prospectively defined toxicity-related treatment terminations after 4 cycles of adjuvant 
chemotherapy, and the toxicity profile were primary endpoints and prospectively 
documented.  
Adverse events (using Common Toxicity Criteria v3.0 25) were evaluated and graded 
at every visit, and causality of treatment was assessed. Dose de-escalation rules are detailed in 
Suppl. Table 1. Severe adverse events were handled by a safety board following international 
guidelines. An external data safety monitoring board supervised the trial. 
An arbitrary cut-off of 45 years was used in a post-hoc analyses to compare toxicity in 
younger vs. older patients.  
 
Efficacy 
Event free (EFS), progression free (PFS) and overall survival (OS) at 3 and 5 years 
were secondary endpoints and recorded at each site visit. EFS was defined as time from study 
inclusion to disease progression, death, or discontinuation of treatment. PFS was a combined 
imaging and clinical endpoint adapted to the response assessment in neuro-oncology (RANO) 
criteria 26 and defined as time from study inclusion to disease progression or death. OS was 
calculated from study inclusion to death.  
 
Health-related quality of life evaluation 
Health-related quality of life (HRQoL) was prospectively evaluated before radio-
chemotherapy, after radio-chemotherapy, and each three months thereafter using EORTC 
QLQ-C30 and QLQ-BN20 27. Role, cognitive and social functioning were defined for the 
primary analyses to reduce errors from multiple testing. The other scales were analyzed on an 
exploratory basis. A difference in the mean value of HRQoL parameters of ≥10 points was 
set to be ‘clinically meaningful’ 28. 
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Cognitive testing 
Cognition was prospectively evaluated at baseline before radio-chemotherapy, after 
radio-chemotherapy, and each three months thereafter. The Controlled Oral Word 
Association Test (COWA 29) was used to measure lexical verbal fluency. Semantic verbal 
fluency was measured by the Regensburger Wortflüssigkeitstest (RWT; 30). Verbal working-
memory was measured with the digit span forward and backward from the German version of 
the WAIS-R 31. TrailMaking Tests (Parts A and B) were used to measure complex visual 
perceptual tracking, planning and flexibility 32. Raw scores were transformed into adjusted z-
scores, and a mean z-score was calculated, indicating group performance. Performance not 
reaching a z-score of -1 was described as impaired. A healthy control population matched for 
age, gender and education was used. 
 
Statistical analysis 
In this prospective descriptive trial, aA total of 30 patients was considered to be the 
minimum population to evaluate feasibility. The incidence of treatment terminations within 
the first 4 cycles of chemotherapy was determined as the primary endpoint to measure 
feasibility 33. Based on published data 34, an incidence of more than 60% toxicity-related 
treatment terminations was defined as inacceptable. Subsequently, the treatment would be 
feasible if the upper limit of the 95%-confidence was below 60%. we hypothesized that if the 
study population consists of 30 patients, and less than 18 patients (60%) or maximally 17 
patients (56.7%) would have to terminate treatment due to toxicity, the primary endpoint 
would be metWith a study population of 30 patients, the primary endpoint was therefore 
reached if at least 17 of 30 patients (56.7%) would receive at least four cycles of maintenance 
chemotherapy, or 44.3% would not be terminated before four cycles were concluded (p1) 
(NQuery 4.0; Statistical Solutions, Boston, USA).  
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All primary end point data are presented descriptively. The 3 year EFS / PFS rate was 
estimated by using binary proportions. PFS and OS analysis was performed using the Kaplan-
Meier method. Correlations between data groups were evaluated by Spearman Rank analysis. 
Comparative statistical analysis for rates and proportions was performed using Chi square 
analysis. For two group comparison, Wilcoxon rank-sum tests were computed. The 
significance level was defined as p<0.05 (Stata 14; StataCorp LP, College Station, Texas, 
USA). 
 
Results 
 
Patient characteristics 
From 2009 to 2014, 33 patients were included at 15 German centers. Thirty patients 
were evaluable, and 25 of them (83.3%) were treated per protocol (Suppl. Figure 1). Median 
age was 37 (range, 21-53), the median Karnofsky Performance Status (KPS) at inclusion was 
90 (range, 50-100), and 77.0% of patients had a KPS of 90 or above at baseline (Table 1).  
 
Imaging (MRI) classification 
Most tumors were lateral/hemispheric (Table 1), and 6.7% of patients showed signs of 
leptomeningeal spread (Table 1 and 2). M2 and M3 disease was only diagnosed during MRI 
reference evaluation. These patients were included in the study based on local evaluation.  
Enhancing tumor was completely resected in 15 patients (Suppl. Table 2). After 
combined radio-chemotherapy, 73.3% of patients had a complete response (Suppl. Table 2). 
No patient progressed before starting adjuvant chemotherapy.  
 
Chang classification 
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Twenty-six of 30 tumors were classifiable, showing a mixed pattern (Table 2). If 
evaluations were based on local readings, the incidence of M2 and M3 disease was much 
lower (6.7% of patients; n=2). 
 
Histological and genetic classification and CSF evaluation 
Each 50% of tumors were into the classic and desmoplastic/nodular entities (Table 1; 
Figure 1). Twenty-nine of 30 patients could be assigned to genetically defined entities by 
immunohistochemistry, and 23 of these were evaluable by 450k methylation classification 35 
with congruent results (Table 1). CTNNB1 exon 3 was mutated in all 4 WNT-activated 
tumors (D32V, S33F, S33P, S37Y). Whole genomic copy number and allelic distribution 
were analyzed without evidence for amplifications of MYC, MYCN or GLI2. One SHH-
activated tumor showed copy number losses 9q and chr14, typical for SHH-activated 
subgroups. However, 17p losses (TP53) were not found in SHH-activated cases, which is in 
line with the absence of TP53 accumulation (Figure 1).  
Twenty-six of 30 patients (86.6%) had a lumbar puncture at diagnosis. Three patients 
were diagnosed with leptomeningeal spread on lumbar CSF evaluation, one of them with 
central review that verified the diagnosis (Table 1). Central review was performed only in the 
minority of cases (9/30 patients; 1 of them with discrepancy in between local and central). 
Lumbar punctures after diagnosis were only performed if meningeosis was suspected, and no 
systematic data could be raised.  
 
Feasibility and toxicity 
All patients were treated with standard photon-based radiotherapy. Radio-
chemotherapy was completed in all patients (Table 3). Two patients terminated therapy 
before maintenance chemotherapy was started, one with tuberculosis and paralytic ileus, and 
one with pneumonia with sepsis. Two patients were lost because they withdrew informed 
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consent, and one patient changed to a local institution after radio-chemotherapy, which was 
not registered as study site. Seventy percent of patients (n=21) tolerated at least four cycles of 
chemotherapy, all of them with dose modifications. Therefore, the pre-specified feasibility 
goal of at least 45%more than 60% of patients receiving at least 4 cycles of maintenance 
chemotherapy was met.  
One patient progressed after the fifth adjuvant cycle. All other patients were 
discontinued due to treatment-related toxicity or withdrawal of informed consent (Table 3). 
Seventy-seven out of 155 cycles were given per protocol (49.7%; Table 3 and Suppl. Figure 
2A and B).   
Leukopenia was the major toxicity. Polyneuropathy and ototoxicity were the only 
grade 3 or 4 non-hematological toxicities (Table 4). Six patients had grade I, 4 patients grade 
2, and 4 patients grade 3 polyneuropathy.  
Events were also calculated as events per cycle and showed an increase of toxicity 
over treatment time (Table 4, Suppl. Table 3, and Suppl. Figure 2B). Treatment was 
terminated or dose intensity was reduced in almost 60% of patients at cycle 4 due to side 
effects (Suppl. Figure 2B). Of note, Vincristine was stopped early on in a large number of 
patients, whereas lumustine and cisplatin were typically stopped later in the course of 
treatment. The number of severe adverse events per patient was highly variable (range 0-23). 
Feasibility appeared to be age-dependent. Post-hoc analyses showed that 72.7% of 
patients below age 45 received four cycles of chemotherapy, but only 62.5% of patients older 
than 45. Testing for all eight adjuvant cycles revealed that 45.5% of all patients younger than 
45 years completed eight cycles, whereas only 12.5% of patients over 45 years received all 
cycles. Severe adverse events were significantly more frequent in patients older than 45 years 
of age (p = 0.040). We observed no treatment-related deaths.  
 
Health-related quality of Life  
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Compliance to HRQoL evaluation was > 65% at most time points (Suppl. Table 4). 
Scoring was reduced (≥10 points) in role, cognitive and social functioning directly post-
operative, where role and social functioning was also significantly worse in comparison to a 
glioblastoma population 36,37 (Suppl. Table 5). On a group level, role, cognitive and social 
functioning improved over time (Figure 2). Similar results were found for the exploratory 
HRQoL items (Suppl. Figure 3). 
 
Cognition  
Compliance to cognition testing was 44.5%. On a group level, scores for working 
memory remained within normal limits. Attention was impaired at all time points, and visual 
perception was impaired at the first and the second measurement, but returned to normal in 
the third measurement with a mean performance above z=-1. Lexical verbal fluency 
(Controlled Oral Word Association Test COWA, n=7, M1=-1.8, M3=-0.6, p<0.02) and 
semantic verbal fluency (food naming, n=7, M1=-1.92, M3=-0.42, p<005) were impaired 
before radio-chemotherapy, but reached an average level of z=-0.84 and z=-1.0 in the third 
measurement, indicating improvement to normal (Suppl. Figure 4).  
 
Efficacy 
At databank lock (June 1st, 2016), median follow-up was 58.0 months, and a total of 
seven patients had relapsed, amongst them one patient with M3 disease (CMB, genetic entity 
Non-WNT/Non-SHH; no MYC/MYCN amplification or TP53 mutation), one patient with 
Non-WNT/Non-SHH M0, and five patients with SHH-activated tumors, none of them with 
p53 mutation or MYCN amplification. (Table 1). Three patients died in the treatment phase, 
all from tumor-related complications (epileptic seizure in the bathtub, aspiration pneumonia, 
and suicide). 
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The 3-year EFS rate was 66.6%, the 3 year PFS and OS rates were 66.6%. and 70.0% 
respectively. With 83% patients without progression and 90% of all patients still alive, 
median PFS and OS were not reached. Genetic subgroups were not pre-specified to be 
explored for efficacy due to limited patient numbers.  
 
Correlation analysis 
Only one of the Non-WNT/Non-SHH (Group 4) tumors was Chang M3 at diagnosis. 
Almost all tumors with a lateral localization in MRI were SHH-activated (90.9%) (p = 0.040). 
Non-WNT/Non-SHH-activated tumors were lateral in 20% of cases, and not a single WNT-
activated tumor was lateral (p = 0.01). Both, lateral location and SHH-activation were 
associated with a higher proportion of complete resections (63.6% vs. 36.8%; p=0.018 and 
45.3% vs. 38.7%; p=0.026). Accordingly, after volumetric evaluation of MRI, complete 
tumor resections were more prevalent in the SHH-activated tumors (97.5% vs. 86.9%; 
p=0.024). 
Relapses were more prevalent in the SHH-activated tumors (80% of recurrent cases 
were SHH vs. 64% of non-recurrent cases; p = 0.091) (Suppl. Table 6). 
 
Discussion 
 
NOA-07 is a prospective descriptive trial to evaluate feasibility and toxicity of 
combined radio-polychemotherapy in adults with newly diagnosed medulloblastoma. The 
primary endpoint, the number of toxicity-related treatment terminations after 4 cycles of 
adjuvant chemotherapy, was justified retrospectively by upcoming data that suggest that a 
decreased number of treatment cycles is not decisive for progression-free or overall survival 
in children with average-risk medulloblastoma 38. The regimen was feasible for at least four 
cycles of maintenance chemotherapy in 70.0% of patients. The pre-specified study goal of at 
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leastthat more than 18 patients (4560% of patients) could be treated with at least 4 cycles of 
chemotherapy was therefore met. Considerable and increasing toxicity was observed, with 
polyneuropathy as the main non-hematological toxicity occurring early within treatment, and 
leukopenia and thrombocytopenia as the most prevalent hematological toxicities. Sixty-seven 
percent of patients went off-study due to toxicity under maintenance chemotherapy. We 
therefore conclude that the regimen induces more severe toxicity than in comparable pediatric 
trials.  
Recent publications suggest that Vincristine, that induces a high rate of neurotoxicity, 
may be fully deleted without endangering efficacy 39, and that alternative agents may possibly 
replace vincristine during concomitant radio-chemotherapy 40. In addition, attenuated 
maintenance regimen may decrease toxicity while sustaining efficacy 41. 
With adherence to strict de-escalation rules, toxicity was manageable. No unexpected 
severe adverse events were recorded. In a non-randomized retrospectively evaluated cohort of 
young adults treated with the same regimen 14, 28 of 47 patients (59.6%) received the full 
number of eight maintenance chemotherapy cycles. Median age was 37.0 in our trial and 28.5 
years in the other cohort. This difference in age may indicate decreased feasibility in older 
patients. Accordingly, feasibility was age-dependent in NOA-07, with a higher rate of adverse 
and a significantly higher rate of severe adverse events in patients above age 45. 
Long-term neurotoxicity is a major concern in radio-chemotherapy regimens involving 
the brain 5,42,43. In a Canadian trial that focused on medulloblastoma patients in their second 
life decade, long-term ototoxicity and neurotoxicity of CTC grade 2 or above occurred in 
45.0% and 71.0% of patients 5. Long-term toxicity results of NOA-07 are lacking due to the 
short follow-up time of 58.0 months in median and will be reported after all patients have 
been followed for 5 years. 
HRQoL and cognition are important correlates of toxicity and long-term outcomes. 
During the active treatment phase of NOA-07, HRQoL and cognitive function improved. 
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Long-term data will be supplemented by a social outcome analysis that will mainly focus on 
long-term social function. 
Study results from Packer and co-workers indicate that radiotherapy plus concomitant 
and adjuvant chemotherapy is superior to radiotherapy alone in children 10,12,44. Patients in the 
Friedrich trial 14 experienced a 4-year event-free survival rate (EFS) of 68.0% and a 4-year 
overall survival (OS) rate of 89.0%, similar to premature data in NOA-07. A recent meta-
analysis by Kocakaya et al. showed that patients receiving chemotherapy first-line survived 
significantly longer (mOS: 108 mo, 95.0% CI: 68.6-148.0) than patients treated with 
radiotherapy alone (mOS: 57 mo, 95.0% CI: 39.6-74.4) 45. Importantly, published data also 
show that the risk of recurrence appears to increase markedly with time 17. In conclusion, 
published evidence strongly indicates a role for combined radio-chemotherapy for adults with 
medulloblastoma, but also warrants long-term follow up in this population. The NOA-07 
protocol , however, is the first trial that evaluated these questions prospectively.  
We further analyzed MR imaging, histological and molecular patterns to detect 
unusual patterns on a descriptive and correlative level. Our results correspond well to 
published results 4,6,20,24,46. Of note, metastatic disease (Chang M1 to M3) was found in one 
third of patients during central review, but only 6.7% in local evaluations. This points to a 
strict central review strategy during diagnostic workup, as metastatic disease is connected to 
worse outcomes 3 and may mandate adapted treatment strategies.  
Reference analysis of medulloblastoma subgroups showed the expected histological 
and genetic distribution. The genetic pattern in WNT-activated adult patients in our dataset 
was different from children and might indicate a different biology and explain the worse 
prognosis 444. The SHH-subgroup is highly overrepresented in adults, and SHH-activated 
tumors had a favorable outcome in infants and young children (5-year OS 77.0%), compared 
to older children (5-year OS 68.0%) and adults (5-year OS 34.0%) 664. In NOA-07, 5 of 7 
early relapses were SHH-activated. All SHH-activated tumors in our series represented the 
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SHH-activated TP53 wildtype entity, none showed MYC/MYCN-amplification, and the 
subgroup comprised a higher rate of complete resections and comparable dose intensities 
during radio-chemotherapy.  
Shortcomings of this trial are limited patient numbers, the distribution of patients to a 
large number of centers that may increase toxicity rates due to lower experience of the 
involved investigators, and the non-randomized design. However, the trial was powered for 
feasibility and toxicity as its primary endpoint. 
In summary, this prospective descriptive trial evaluated feasibility and toxicity of a 
radio-polychemotherapy regimen in a homogenous cohort of intermediate prognostic adults 
with medulloblastoma, as well as imaging, histological and molecular parameters, HRQoL, 
cognition, and EFS, PFS and OS outcomes. Long-term evaluations are ongoing. We conclude 
that combined radio-chemotherapy is associated with considerable toxicity and mandates pre-
defined tapering rules and dose modifications in the majority of patients. Modified regimen 
may increase feasibility of radio-polychemotherapy of adult patients with medulloblastoma. 
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Figure legends  
 
Figure 1 
Histological and genetic distribution in NOA-07. Figure A: Clustering of samples based on 
the 5.000 most differentially methylated CpG probes (standard deviation), with DNA 
methylation values shown from unmethylated (blue) to methylated (red). SHH-activated, 
WNT-activated and Non-WNT/Non-SHH (Group 4) tumors are clearly distinct. DNMB, 
desmoplastic nodular medulloblastoma; CMB classic medulloblastoma. Figure 1B: Summary 
of copy number profiles per molecular subgroup. Log2 copy number ratios (tumor : normal) 
are displayed on a scale from loss (red) to gain (green). Notable changes include monosomy 6 
in one WNT-activated sample, loss of 9q in a subset of SHH-activated tumors, and iso(17q) 
in all three Non-WNT/Non-SHH (Group 4) tumors. 
 
Figure 2 
Health-related quality of life (HRQoL) evaluation (main categories). Scores over time for the three 
preselected scales (role functioning, Figure 2A; cognitive functioning, Figure 2B; and social 
functioning, Figure 2C), with the number of patients with HRQoL data at each time point. 
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Table legends 
 
Table 1 
Baseline patient characteristics. Age, gender, KPS, cranial and spinal MR imaging patterns, lumbar 
punctures (cerebrospinal fluid, CSF), histological and molecular subtype were recorded.  
 
Table 2 
Modified Chang classification 333 evaluated from imaging and CSF patterns. Condensed 
contrast-enhanced T1-w post Gd and T2-w imaging, lumbar puncture results and additional 
staging were included. T stands for primary tumor, M for metastasis. T1 is tumor less than 3 
cm in diameter and limited to midline, roof of the fourth ventricle, and cerebellar 
hemispheres. T2 is tumor more than 3 cm in diameter, invading one adjacent structures or 
partially filling the fourth ventricle. T4 is tumor spreading through the aqueduct of Sylvius, or 
tumor extending to the upper cervical cord. M0 stands for no evidence of metastasis. M1 is 
microscopic tumor cells in the cerebrospinal fluid, M2 is gross nodular seedings demonstrated 
in the subarachnoid space, or ventricles. M3 is gross nodular seeding in the spinal 
subarachnoid space, and M4 is extra-neural metastasis. * indicates missing data due to lacking 
source imaging data. 
 
Table 3 
Treatment compliance and duration. Time to start of each treatment part was calculated from 
time of tumor resection to first day of the respective treatment. Extent of resection was 
calculated from post-operative MRI, and compliance to radio-chemotherapy and maintenance 
chemotherapy was extracted. 
 
Table 4 
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Hematological and non-hematological toxicity Grade 1 & 2 and 3 & 4 according to CTC 
version 3.0. Toxicity was evaluated during radio-chemotherapy and during maintenance 
chemotherapy. Percentages were calculated in relation to patients under treatment at the 
respective time point. 
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Abstract 
 
Background: Medulloblastoma in adult patients is rare, with 0.6 cases per million. 
Prognosis depends on clinical factors and medulloblastoma entity. No prospective data on the 
feasibility of radio-chemotherapy exist. The German Neuro-Oncology Working Group (NOA) 
performed a prospective descriptive multicenter single-arm Phase II trial to evaluate 
feasibility and toxicity of radio-polychemotherapy.  
Methods: The NOA-07 trial combined cranio-spinal irradiation with vincristine, 
followed by eight cycles of cisplatin, lomustine and vincristine. Adverse events, imaging and 
progression patterns, histological and genetic markers, health-related quality of life (HRQoL) 
and cognition were evaluated. Primary endpoint was the rate of toxicity-related treatment 
terminations after four chemotherapy cycles, and the toxicity profile. The feasibility goal was 
reached if at least 45% of patients received at least 4 cycles of maintenance chemotherapy. 
Results: Thirty patients were evaluable. Each 50% percent showed classic and 
desmoplastic-nodular histology. Sixty-seven percent were classified into the sonic hedgehog 
(SHH) subgroup without TP53 alterations, 13% in wingless (WNT), and 17% in Non-
WNT/Non-SHH. Four cycles of chemotherapy were feasible in the majority (n=21; 70.0%). 
Hematological side effects and polyneuropathy were prevalent toxicities. During the active 
treatment period, HRQoL and verbal fluency improved significantly. The 3-year event-free 
survival rate (EFS) was 66.6% at the time of databank lock. 
Conclusions: Radio-polychemotherapy did lead to considerable toxicity and a high 
amount of dose reductions throughout the first four chemotherapy cycles that may affect 
efficacy. Thus, we propose frequent patient surveillance using this regimen. Modifications of 
the regimen may increase feasibility of radio-polychemotherapy of adult patients with 
medulloblastoma. 
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Importance of the study: 
NOA-07 showed that combined radio-chemotherapy followed by maintenance chemotherapy 
with cisplatin, lomustine, and vincristine is more toxic in adults than in children. This 
prospective descriptive trial constitutes a unique dataset that perpetuates the development of 
effective treatments in this curable population. The results have potential to influence or even 
change clinical practice. The NOA-07 protocol can be translated to the recommendation that 
adults with medulloblastoma should be treated with attenuated radio-polychemotherapy 
regimen that consider the decreased feasibility of radio-polychemotherapy in adults in 
comparison to children. In addition, an attenuated NOA-07 regimen may serve as a basis for 
the standard arm in a subsequent trial. Current knowledge makes it likely that such a trial will 
ask a molecular question in its experimental arm and will lead into a molecularly stratified 
approach for adults with medulloblastoma.
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Introduction 
 
Medulloblastoma is rare in adults. About 70% of cases occur in patients younger than 
15 years 1. The US SEER database reports 0.6 cases per million in adults per year 2. Five-year 
overall survival depends on clinical prognostic factors 3, and on histological entity and genetic 
subgroup 4, and reaches 40-90%. Long-term sequelae interfere with functioning in daily life 5. 
Four genetic subgroups (WNT, SHH, Group 3 and Group 4) defined by expression 
patterns and epigenetic signatures allow a reliable prognostication 6. The WHO classification 
(2016, 7) developed this further to a combination of histological criteria with classic (CMB; 
60-70% in adults), desmoplastic/nodular (DNMB; 25-40%), extensive nodular (MBEN; <5%) 
and large cell/anaplastic (LCA, 10-25%) entities and genetically defined groups. These 
consist of WNT-activated, SHH-activated and TP53 wildtype, SHH-activated and TP53 
altered, and Non-WNT/Non-SHH (Group 3 and 4). Patients with MYC/MYCN-amplification 
6,8 and p53 mutation 9 have an inferior prognosis. In adults, group 3 does not exist. 
In children, the introduction of chemotherapy combined with cranio-spinal 
radiotherapy improved survival 10-12, however, associated with significant unwanted effects 13. 
The same regimen was retrospectively evaluated in a non-randomized adult sub-cohort 14. 
Radio-chemotherapy compared to radiotherapy alone improved event-free survival (EFS) (4-
year EFS, 74% v. 47%; p=0.027) and overall survival (OS) (4-year-OS, 94% vs. 81%; 
p=0.035). Retrospective data and small prospective trials also suggested an impact of 
chemotherapy in adult patients 15-17. 
NOA-07 prospectively evaluated toxicity-related treatment terminations after 4 cycles 
of adjuvant chemotherapy, and the toxicity profile in the first-line treatment of adult patients 
with medulloblastoma. Results of the active treatment period are presented here. 
 
Material and Methods 
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Treatment and ethics 
NOA-07 enrolled patients at 15 sites in Germany. The trial was approved by the Ethics 
Committee (EC) of the University of Regensburg, Germany (08-112-0058; substantial 
amendment of July 01, 2016). The trial was registered at ClinicalTrials.gov (NCT01614132). 
All patients with age above 21 and Chang stage T1-4 and M0 or M1 as diagnosed 
locally at the trial sites were included. Treatment consisted of photon cranio-spinal irradiation 
(1.6 Gy/35.2 Gy, posterior fossa boost 1.8 Gy/55 Gy) in combination with vincristine (1.5 
mg/m2 weekly, cap at 2.0 mg), followed by a maximum of eight six-weekly cycles of 
cisplatin (70.0 mg/m2, day 1), lomustine (75.0 mg/m2, day 1) and vincristine (1.5 g/m2, cap at 
2.0 mg, days 1, 8, 15). Treatment per protocol was at least one cycle of adjuvant 
chemotherapy (Suppl. Figure 1).  
 
Imaging (MRI) classification 
Cranio-spinal imaging patterns (MRI with T1-weighted (w) images, T1-w post 
gadolinium-containing contrast agent (Gd), T2-w, FLAIR) were evaluated prospectively. 
Inclusion was based on the local (neuro)radiology report. All imaging was reviewed for 
localization, extent of resection, and progression 18.  
Contrast enhancing and non-enhancing tumor volume was calculated from voxel size 
x3 multiplied with the number of target voxels using the IntelliSpace Portal® (Philips 
Healthcare). Extent of resection was evaluated for the enhancing tumor volume on early 
postsurgical MRI (24 to 72 h post-operative). Tumor progression was assessed on follow-up 
cranio-spinal MRIs after radiotherapy, before starting adjuvant chemotherapy and in 12-
weekly time intervals over three years, and six-monthly intervals thereafter.  
 
Chang classification 
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Despite the fact that the Chang 3 classification was initially based on surgical reports 
and CT scans, and that it´s prognostic value is doubtable, patients were classified according to 
Chang using MRI (condensed T1-w plus gadolinium and T2-w) criteria and results from 
lumbar punctures, with the aim to morphologically describe the study population.  
 
Histological and molecular classification and CSF assessment 
All specimens were diagnosed locally and referenced by at least two experienced 
neuropathologists 19. After introduction of 2016 WHO classification amendment 7, all 
specimens were re-evaluated and an integrated diagnosis was reported.  
Immunohistochemistry was performed as described 20. Genetic entities were defined 
using immunohistochemistry with antibodies against ß-Catenin, Yap1, p75-NGFR, Otx2 and 
p53. DNA was extracted, and direct sequencing (Sanger) of exon 3 of CTNNB1 was 
performed 21. Genome-wide copy number estimation and analysis of allelic distribution was 
performed by molecular inversion profiling (MIP) 22 and analyzed by Nexus Copy Number 
7.0 Discovery Edition software (BioDiscovery, El Segundo, CA, U.S.A.). If minimal DNA 
was available, a multiplex ligation-dependent probe amplification (MLPA) was done 23.  
Global DNA methylation profiling using the Illumina Human Methylation 450 Bead 
Chip array was performed. Medulloblastoma subgrouping were done as described 20,24. 
Genome-wide copy number profiles were generated using the ‘conumee’ package 
(https://www.bioconductor.org/packages/release/bioc/html/conumee.html) in the R 
programming environment. 
As meningeosis in adults with medulloblastoma is not well described, CSF punctures 
were done in all patients at the time of diagnosis and recommended every 3 months thereafter 
or if clinical symptoms occurred. CSF was referenced centrally.  
 
Feasibility and toxicity 
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Prospectively defined toxicity-related treatment terminations after 4 cycles of adjuvant 
chemotherapy, and the toxicity profile were primary endpoints and prospectively 
documented.  
Adverse events (using Common Toxicity Criteria v3.0 25) were evaluated and graded 
at every visit, and causality of treatment was assessed. Dose de-escalation rules are detailed in 
Suppl. Table 1. Severe adverse events were handled by a safety board following international 
guidelines. An external data safety monitoring board supervised the trial. 
An arbitrary cut-off of 45 years was used in a post-hoc analyses to compare toxicity in 
younger vs. older patients.  
 
Efficacy 
Event free (EFS), progression free (PFS) and overall survival (OS) at 3 and 5 years 
were secondary endpoints and recorded at each site visit. EFS was defined as time from study 
inclusion to disease progression, death, or discontinuation of treatment. PFS was a combined 
imaging and clinical endpoint adapted to the response assessment in neuro-oncology (RANO) 
criteria 26 and defined as time from study inclusion to disease progression or death. OS was 
calculated from study inclusion to death.  
 
Health-related quality of life evaluation 
Health-related quality of life (HRQoL) was prospectively evaluated before radio-
chemotherapy, after radio-chemotherapy, and each three months thereafter using EORTC 
QLQ-C30 and QLQ-BN20 27. Role, cognitive and social functioning were defined for the 
primary analyses to reduce errors from multiple testing. The other scales were analyzed on an 
exploratory basis. A difference in the mean value of HRQoL parameters of ≥10 points was 
set to be ‘clinically meaningful’ 28. 
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Cognitive testing 
Cognition was prospectively evaluated at baseline before radio-chemotherapy, after 
radio-chemotherapy, and each three months thereafter. The Controlled Oral Word 
Association Test (COWA 29) was used to measure lexical verbal fluency. Semantic verbal 
fluency was measured by the Regensburger Wortflüssigkeitstest (RWT; 30). Verbal working-
memory was measured with the digit span forward and backward from the German version of 
the WAIS-R 31. TrailMaking Tests (Parts A and B) were used to measure complex visual 
perceptual tracking, planning and flexibility 32. Raw scores were transformed into adjusted z-
scores, and a mean z-score was calculated, indicating group performance. Performance not 
reaching a z-score of -1 was described as impaired. A healthy control population matched for 
age, gender and education was used. 
 
Statistical analysis 
In this prospective descriptive trial, a total of 30 patients was considered to be the 
minimum population to evaluate feasibility. The incidence of treatment terminations within 
the first 4 cycles of chemotherapy was determined as the primary endpoint to measure 
feasibility 33. Based on published data 34, we hypothesized that if the study population 
consists of 30 patients, and less than 18 patients (60%) or maximally 17 patients (56.7%) 
would have to terminate treatment due to toxicity, the primary endpoint would be met 
(NQuery 4.0; Statistical Solutions, Boston, USA).  
All primary end point data are presented descriptively. The 3 year EFS / PFS rate was 
estimated by using binary proportions. PFS and OS analysis was performed using the Kaplan-
Meier method. Correlations between data groups were evaluated by Spearman Rank analysis. 
Comparative statistical analysis for rates and proportions was performed using Chi square 
analysis. For two group comparison, Wilcoxon rank-sum tests were computed. The 
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significance level was defined as p<0.05 (Stata 14; StataCorp LP, College Station, Texas, 
USA). 
 
Results 
 
Patient characteristics 
From 2009 to 2014, 33 patients were included at 15 German centers. Thirty patients 
were evaluable, and 25 of them (83.3%) were treated per protocol (Suppl. Figure 1). Median 
age was 37 (range, 21-53), the median Karnofsky Performance Status (KPS) at inclusion was 
90 (range, 50-100), and 77.0% of patients had a KPS of 90 or above at baseline (Table 1).  
 
Imaging (MRI) classification 
Most tumors were lateral/hemispheric (Table 1), and 6.7% of patients showed signs of 
leptomeningeal spread (Table 1 and 2). M2 and M3 disease was only diagnosed during MRI 
reference evaluation. These patients were included in the study based on local evaluation.  
Enhancing tumor was completely resected in 15 patients (Suppl. Table 2). After 
combined radio-chemotherapy, 73.3% of patients had a complete response (Suppl. Table 2). 
No patient progressed before starting adjuvant chemotherapy.  
 
Chang classification 
Twenty-six of 30 tumors were classifiable, showing a mixed pattern (Table 2). If 
evaluations were based on local readings, the incidence of M2 and M3 disease was much 
lower (6.7% of patients; n=2). 
 
Histological and genetic classification and CSF evaluation 
Each 50% of tumors were into the classic and desmoplastic/nodular entities (Table 1; 
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Figure 1). Twenty-nine of 30 patients could be assigned to genetically defined entities by 
immunohistochemistry, and 23 of these were evaluable by 450k methylation classification 35 
with congruent results (Table 1). CTNNB1 exon 3 was mutated in all 4 WNT-activated 
tumors (D32V, S33F, S33P, S37Y). Whole genomic copy number and allelic distribution 
were analyzed without evidence for amplifications of MYC, MYCN or GLI2. One SHH-
activated tumor showed copy number losses 9q and chr14, typical for SHH-activated 
subgroups. However, 17p losses (TP53) were not found in SHH-activated cases, which is in 
line with the absence of TP53 accumulation (Figure 1).  
Twenty-six of 30 patients (86.6%) had a lumbar puncture at diagnosis. Three patients 
were diagnosed with leptomeningeal spread on lumbar CSF evaluation, one of them with 
central review that verified the diagnosis (Table 1). Central review was performed only in the 
minority of cases (9/30 patients; 1 of them with discrepancy in between local and central). 
Lumbar punctures after diagnosis were only performed if meningeosis was suspected, and no 
systematic data could be raised.  
 
Feasibility and toxicity 
All patients were treated with standard photon-based radiotherapy. Radio-
chemotherapy was completed in all patients (Table 3). Two patients terminated therapy 
before maintenance chemotherapy was started, one with tuberculosis and paralytic ileus, and 
one with pneumonia with sepsis. Two patients were lost because they withdrew informed 
consent, and one patient changed to a local institution after radio-chemotherapy, which was 
not registered as study site. Seventy percent of patients (n=21) tolerated at least four cycles of 
chemotherapy, all of them with dose modifications. Therefore, the pre-specified feasibility 
goal of more than 60% of patients receiving at least 4 cycles of maintenance chemotherapy 
was met.  
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One patient progressed after the fifth adjuvant cycle. All other patients were 
discontinued due to treatment-related toxicity or withdrawal of informed consent (Table 3). 
Seventy-seven out of 155 cycles were given per protocol (49.7%; Table 3 and Suppl. Figure 
2A and B).   
Leukopenia was the major toxicity. Polyneuropathy and ototoxicity were the only 
grade 3 or 4 non-hematological toxicities (Table 4). Six patients had grade I, 4 patients grade 
2, and 4 patients grade 3 polyneuropathy.  
Events were also calculated as events per cycle and showed an increase of toxicity 
over treatment time (Table 4, Suppl. Table 3, and Suppl. Figure 2B). Treatment was 
terminated or dose intensity was reduced in almost 60% of patients at cycle 4 due to side 
effects (Suppl. Figure 2B). Of note, Vincristine was stopped early on in a large number of 
patients, whereas lumustine and cisplatin were typically stopped later in the course of 
treatment. The number of severe adverse events per patient was highly variable (range 0-23). 
Feasibility appeared to be age-dependent. Post-hoc analyses showed that 72.7% of 
patients below age 45 received four cycles of chemotherapy, but only 62.5% of patients older 
than 45. Testing for all eight adjuvant cycles revealed that 45.5% of all patients younger than 
45 years completed eight cycles, whereas only 12.5% of patients over 45 years received all 
cycles. Severe adverse events were significantly more frequent in patients older than 45 years 
of age (p = 0.040). We observed no treatment-related deaths.  
 
Health-related quality of Life  
Compliance to HRQoL evaluation was > 65% at most time points (Suppl. Table 4). 
Scoring was reduced (≥10 points) in role, cognitive and social functioning directly post-
operative, where role and social functioning was also significantly worse in comparison to a 
glioblastoma population 36,37 (Suppl. Table 5). On a group level, role, cognitive and social 
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functioning improved over time (Figure 2). Similar results were found for the exploratory 
HRQoL items (Suppl. Figure 3). 
 
Cognition  
Compliance to cognition testing was 44.5%. On a group level, scores for working 
memory remained within normal limits. Attention was impaired at all time points, and visual 
perception was impaired at the first and the second measurement, but returned to normal in 
the third measurement with a mean performance above z=-1. Lexical verbal fluency 
(Controlled Oral Word Association Test COWA, n=7, M1=-1.8, M3=-0.6, p<0.02) and 
semantic verbal fluency (food naming, n=7, M1=-1.92, M3=-0.42, p<005) were impaired 
before radio-chemotherapy, but reached an average level of z=-0.84 and z=-1.0 in the third 
measurement, indicating improvement to normal (Suppl. Figure 4).  
 
Efficacy 
At databank lock (June 1st, 2016), median follow-up was 58.0 months, and a total of 
seven patients had relapsed, amongst them one patient with M3 disease (CMB, genetic entity 
Non-WNT/Non-SHH; no MYC/MYCN amplification or TP53 mutation), one patient with 
Non-WNT/Non-SHH M0, and five patients with SHH-activated tumors, none of them with 
p53 mutation or MYCN amplification. (Table 1). Three patients died in the treatment phase, 
all from tumor-related complications (epileptic seizure in the bathtub, aspiration pneumonia, 
and suicide). 
The 3-year EFS rate was 66.6%, the 3 year PFS and OS rates were 66.6%. and 70.0% 
respectively. With 83% patients without progression and 90% of all patients still alive, 
median PFS and OS were not reached. Genetic subgroups were not pre-specified to be 
explored for efficacy due to limited patient numbers.  
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Correlation analysis 
Only one of the Non-WNT/Non-SHH (Group 4) tumors was Chang M3 at diagnosis. 
Almost all tumors with a lateral localization in MRI were SHH-activated (90.9%) (p = 0.040). 
Non-WNT/Non-SHH-activated tumors were lateral in 20% of cases, and not a single WNT-
activated tumor was lateral (p = 0.01). Both, lateral location and SHH-activation were 
associated with a higher proportion of complete resections (63.6% vs. 36.8%; p=0.018 and 
45.3% vs. 38.7%; p=0.026). Accordingly, after volumetric evaluation of MRI, complete 
tumor resections were more prevalent in the SHH-activated tumors (97.5% vs. 86.9%; 
p=0.024). 
Relapses were more prevalent in the SHH-activated tumors (80% of recurrent cases 
were SHH vs. 64% of non-recurrent cases; p = 0.091) (Suppl. Table 6). 
 
Discussion 
 
NOA-07 is a prospective descriptive trial to evaluate feasibility and toxicity of 
combined radio-polychemotherapy in adults with newly diagnosed medulloblastoma. The 
primary endpoint, the number of toxicity-related treatment terminations after 4 cycles of 
adjuvant chemotherapy, was justified retrospectively by upcoming data that suggest that a 
decreased number of treatment cycles is not decisive for progression-free or overall survival 
in children with average-risk medulloblastoma 38. The regimen was feasible for at least four 
cycles of maintenance chemotherapy in 70.0% of patients. The pre-specified study goal that 
more than 18 patients (60%) could be treated with at least 4 cycles of chemotherapy was 
therefore met. Considerable and increasing toxicity was observed, with polyneuropathy as the 
main non-hematological toxicity occurring early within treatment, and leukopenia and 
thrombocytopenia as the most prevalent hematological toxicities. Sixty-seven percent of 
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patients went off-study due to toxicity under maintenance chemotherapy. We therefore 
conclude that the regimen induces more severe toxicity than in comparable pediatric trials.  
Recent publications suggest that Vincristine, that induces a high rate of neurotoxicity, 
may be fully deleted without endangering efficacy 39, and that alternative agents may possibly 
replace vincristine during concomitant radio-chemotherapy 40. In addition, attenuated 
maintenance regimen may decrease toxicity while sustaining efficacy 41. 
With adherence to strict de-escalation rules, toxicity was manageable. No unexpected 
severe adverse events were recorded. In a non-randomized retrospectively evaluated cohort of 
young adults treated with the same regimen 14, 28 of 47 patients (59.6%) received the full 
number of eight maintenance chemotherapy cycles. Median age was 37.0 in our trial and 28.5 
years in the other cohort. This difference in age may indicate decreased feasibility in older 
patients. Accordingly, feasibility was age-dependent in NOA-07, with a higher rate of adverse 
and a significantly higher rate of severe adverse events in patients above age 45. 
Long-term neurotoxicity is a major concern in radio-chemotherapy regimens involving 
the brain 5,42,43. In a Canadian trial that focused on medulloblastoma patients in their second 
life decade, long-term ototoxicity and neurotoxicity of CTC grade 2 or above occurred in 
45.0% and 71.0% of patients 5. Long-term toxicity results of NOA-07 are lacking due to the 
short follow-up time of 58.0 months in median and will be reported after all patients have 
been followed for 5 years. 
HRQoL and cognition are important correlates of toxicity and long-term outcomes. 
During the active treatment phase of NOA-07, HRQoL and cognitive function improved. 
Long-term data will be supplemented by a social outcome analysis that will mainly focus on 
long-term social function. 
Study results from Packer and co-workers indicate that radiotherapy plus concomitant 
and adjuvant chemotherapy is superior to radiotherapy alone in children 10,12,44. Patients in the 
Friedrich trial 14 experienced a 4-year event-free survival rate (EFS) of 68.0% and a 4-year 
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overall survival (OS) rate of 89.0%, similar to premature data in NOA-07. A recent meta-
analysis by Kocakaya et al. showed that patients receiving chemotherapy first-line survived 
significantly longer (mOS: 108 mo, 95.0% CI: 68.6-148.0) than patients treated with 
radiotherapy alone (mOS: 57 mo, 95.0% CI: 39.6-74.4) 45. Importantly, published data also 
show that the risk of recurrence appears to increase markedly with time 17. In conclusion, 
published evidence strongly indicates a role for combined radio-chemotherapy for adults with 
medulloblastoma, but also warrants long-term follow up in this population. The NOA-07 
protocol is the first trial that evaluated these questions prospectively.  
We further analyzed MR imaging, histological and molecular patterns to detect 
unusual patterns on a descriptive and correlative level. Our results correspond well to 
published results 4,6,20,24,46. Of note, metastatic disease (Chang M1 to M3) was found in one 
third of patients during central review, but only 6.7% in local evaluations. This points to a 
strict central review strategy during diagnostic workup, as metastatic disease is connected to 
worse outcomes 3 and may mandate adapted treatment strategies.  
Reference analysis of medulloblastoma subgroups showed the expected histological 
and genetic distribution. The genetic pattern in WNT-activated adult patients in our dataset 
was different from children and might indicate a different biology and explain the worse 
prognosis 444. The SHH-subgroup is highly overrepresented in adults, and SHH-activated 
tumors had a favorable outcome in infants and young children (5-year OS 77.0%), compared 
to older children (5-year OS 68.0%) and adults (5-year OS 34.0%) 664. In NOA-07, 5 of 7 
early relapses were SHH-activated. All SHH-activated tumors in our series represented the 
SHH-activated TP53 wildtype entity, none showed MYC/MYCN-amplification, and the 
subgroup comprised a higher rate of complete resections and comparable dose intensities 
during radio-chemotherapy.  
Shortcomings of this trial are limited patient numbers, the distribution of patients to a 
large number of centers that may increase toxicity rates due to lower experience of the 
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involved investigators, and the non-randomized design. However, the trial was powered for 
feasibility and toxicity as its primary endpoint. 
In summary, this prospective descriptive trial evaluated feasibility and toxicity of a 
radio-polychemotherapy regimen in a homogenous cohort of intermediate prognostic adults 
with medulloblastoma, as well as imaging, histological and molecular parameters, HRQoL, 
cognition, and EFS, PFS and OS outcomes. Long-term evaluations are ongoing. We conclude 
that combined radio-chemotherapy is associated with considerable toxicity and mandates pre-
defined tapering rules and dose modifications in the majority of patients. Modified regimen 
may increase feasibility of radio-polychemotherapy of adult patients with medulloblastoma. 
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Figure legends  
 
Figure 1 
Histological and genetic distribution in NOA-07. Figure A: Clustering of samples based on 
the 5.000 most differentially methylated CpG probes (standard deviation), with DNA 
methylation values shown from unmethylated (blue) to methylated (red). SHH-activated, 
WNT-activated and Non-WNT/Non-SHH (Group 4) tumors are clearly distinct. DNMB, 
desmoplastic nodular medulloblastoma; CMB classic medulloblastoma. Figure 1B: Summary 
of copy number profiles per molecular subgroup. Log2 copy number ratios (tumor : normal) 
are displayed on a scale from loss (red) to gain (green). Notable changes include monosomy 6 
in one WNT-activated sample, loss of 9q in a subset of SHH-activated tumors, and iso(17q) 
in all three Non-WNT/Non-SHH (Group 4) tumors. 
 
Figure 2 
Health-related quality of life (HRQoL) evaluation (main categories). Scores over time for the three 
preselected scales (role functioning, Figure 2A; cognitive functioning, Figure 2B; and social 
functioning, Figure 2C), with the number of patients with HRQoL data at each time point. 
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Table legends 
 
Table 1 
Baseline patient characteristics. Age, gender, KPS, cranial and spinal MR imaging patterns, lumbar 
punctures (cerebrospinal fluid, CSF), histological and molecular subtype were recorded.  
 
Table 2 
Modified Chang classification 333 evaluated from imaging and CSF patterns. Condensed 
contrast-enhanced T1-w post Gd and T2-w imaging, lumbar puncture results and additional 
staging were included. T stands for primary tumor, M for metastasis. T1 is tumor less than 3 
cm in diameter and limited to midline, roof of the fourth ventricle, and cerebellar 
hemispheres. T2 is tumor more than 3 cm in diameter, invading one adjacent structures or 
partially filling the fourth ventricle. T4 is tumor spreading through the aqueduct of Sylvius, or 
tumor extending to the upper cervical cord. M0 stands for no evidence of metastasis. M1 is 
microscopic tumor cells in the cerebrospinal fluid, M2 is gross nodular seedings demonstrated 
in the subarachnoid space, or ventricles. M3 is gross nodular seeding in the spinal 
subarachnoid space, and M4 is extra-neural metastasis. * indicates missing data due to lacking 
source imaging data. 
 
Table 3 
Treatment compliance and duration. Time to start of each treatment part was calculated from 
time of tumor resection to first day of the respective treatment. Extent of resection was 
calculated from post-operative MRI, and compliance to radio-chemotherapy and maintenance 
chemotherapy was extracted. 
 
Table 4 
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Hematological and non-hematological toxicity Grade 1 & 2 and 3 & 4 according to CTC 
version 3.0. Toxicity was evaluated during radio-chemotherapy and during maintenance 
chemotherapy. Percentages were calculated in relation to patients under treatment at the 
respective time point. 
 
 1 
Table 1 
Baseline patient characteristics. Age, gender, KPS, cranial and spinal MR imaging patterns, lumbar 
punctures (cerebrospinal fluid, CSF), histological and molecular subtype were recorded.  
 
Characteristic mean± SD  
range / n / percent of total 
Age at diagnosis  
 
37.2 ±10 years 
range: 21.7-53.7 years 
 
Gender  
 
Male 
Female 
 
 
19 (63.3%) 
11 (36.7%) 
 
KPS (at inclusion) 
 
100 
90 
80 
70 
60 
50 
40-0 
 
 
8 (26.7%) 
15 (50.0%) 
2 (6.7%) 
3 (10.0%) 
1 (3.3%) 
1 (3.3%) 
0 (0.0%) 
 
Localization  
Table 1
 2 
 
Lateral/Hemispheric 
Midline 
With involvement of cerebellar peduncle 
Midline and peduncular 
Not available 
 
 
11 (36.7%) 
8 (26.7%) 
6 (20.0%) 
1 (3.3%) 
4 (13.3%) 
Leptomeningeal spread in MRI 
 
9 (30.0%) 
 
Leptomeningeal spread in lumbar 
puncture 
 
3 (10.0%) 
Histological entity (n=30) 
 
Classic 
Desmoplastic-nodular  
Anaplastic 
Other 
 
 
15 (50%) 
15 (50%) 
0 (0%) 
0 (0%) 
Genetic entity (n=29) 
 
SHH 
WNT 
Group 4 
Not available 
 
 
20 (66.7%) 
4 (13.3%) 
5 (16.7%) 
1 (3.3%) 
 
 
 1 
Table 2 
Modified Chang classification [3] evaluated from imaging and CSF patterns. Condensed 
contrast-enhanced T1-w post Gd and T2-w imaging, lumbar puncture results and additional 
staging were included. T stands for primary tumor, M for metastasis. T1 is tumor less than 3 
cm in diameter and limited to midline, roof of the fourth ventricle, and cerebellar 
hemispheres. T2 is tumor more than 3 cm in diameter, invading one adjacent structures or 
partially filling the fourth ventricle. T4 is tumor spreading through the aqueduct of Sylvius, or 
tumor extending to the upper cervical cord. M0 stands for no evidence of metastasis. M1 is 
microscopic tumor cells in the cerebrospinal fluid, M2 is gross nodular seedings demonstrated 
in the subarachnoid space, or ventricles. M3 is gross nodular seeding in the spinal 
subarachnoid space, and M4 is extra-neural metastasis. * indicates missing data due to lacking 
source imaging data. 
 
  T1 (n) T2 (n) T3a (n) T3b (n) T4 (n) Total (n/%) 
M0 (n) 2 3 8 1 1 15 (50.0%) 
M1 (n) 0 0 0 0 0 0 (0%) 
M2 (n) 0 0 8 0 1 9 (30.0%) 
M3 (n) 0 0 1 0 0 1 (3.3%) 
M4 (n) 0 0 0 0 0 0 (0%) 
Total (n/%) 2 (6.7%) 3 (10.0%) 17 (56.7%) 1 (3.3)% 2 (6.6%) 26 (86.7%)* 
 
 
Table 2
 1 
Table 3 
Treatment compliance and duration. Time to start of each treatment part was calculated from 
time of tumor resection to first day of the respective treatment. Extent of resection was 
calculated from post-operative MRI, and compliance to radio-chemotherapy and maintenance 
chemotherapy was extracted. Data were calculated in the “intent to treat population”. 
 
Characteristic n / percent of total  
days 
mean± SD  
Resection 
 
Interval from diagnosis to resection 
 
Resection compliance 
 
Grade of resection 
Complete 
Partial 
Biopsy 
Data not available 
 
Average percentage of resection (in MRI) 
 
 
 
10 ± 15.2 
 
30 (100%) 
 
 
15 (50.0%) 
8 (26.7%) 
0 (0.0%) 
7 (23.3%) 
 
94.7% ± 12.4% 
 
Radio-chemotherapy 
 
Number of patients (median days; % of 
total) 
Table 3
 2 
Interval from resection to radio-chemotherapy 
Interval from radio-chemotherapy to adjuvant 
chemotherapy 
 
Radiotherapy per protocol 
 
Concomitant chemotherapy 
   Less than 4 doses of VCR 
   4-6 doses of VCR 
   7-8 doses of VCR 
 
53.0 ± 24 
48.0 ± 79 
 
 
30 (100 %) 
 
 
2 (6.6%) 
16 (53.3%) 
12 (40.0%) 
Maintenance chemotherapy 
 
Interval from resection to adjuvant chemotherapy 
 
Drop-out rate 
     by cycle 1  
     by cycle 2 
     by cycle 3 
     by cycle 4 
     by cycle 5 
     by cycle 6 
     by cycle 7 
     by cycle 8 
 
Number of patients (% of total) 
 
166 ± 76.5 
 
 
5 (16.7%)  
5 (16.7%)  
9 (30.0%) 
9 (30.0%) 
9 (30.0%) 
11 (36.7%) 
17 (56.7%) 
20 (66.7%) 
 
 3 
Cycles of chemotherapy given 
Cycles given per protocol 
 
155 (100%) 
77 (49.7%) 
 
 
 1 
Table 4 
Hematological and non-hematological toxicity Grade 1 & 2 and 3 & 4 according to CTC 
version 3.0. Toxicity was evaluated during radio-chemotherapy and during maintenance 
chemotherapy. Percentages were calculated in relation to patients under treatment at the 
respective time point. 
 
Toxicity type Radio-
Chemotherapy 
(% of affected 
patients) 
Radio-
Chemotherapy 
(no. of events) 
Adjuvant 
chemotherapy 
(% of affected 
patients) 
Adjuvant 
chemotherapy 
(no. of events) 
Active 
treatment 
phase 
(% of 
affected 
patients) 
Active 
treatment 
phase 
(no. of 
events) 
Grade 1 & 2       
Leukopenia 53.3 16 66.7  62 76.7 78 
Thrombocytopenia 56.7 17 50.0  46 76.7 63 
Anemia 70.0 21 40.0 111 86.7 132 
Infection 23.3 7 16.7 12 30.0 19 
Nausea 66.7 20 46.7 39 73.3 59 
Emesis 30.0 9 16.7 13 36.7 22 
Polyneuropathy 30.0 9 63.3  81 70.0 81 
Ototoxicity 10.0 3 23.3 33 23.3 36 
Grade 3 & 4       
Leukopenia 36.7 11 66.7 68 56.7 79 
Thrombocytopenia 3.3 1 36.7 33 40.0 34 
Anemia 13.3 4 20.0 20 20.0 24 
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Infection 10.0 3 0.0 0 20.0 3 
Nausea 6.7 2 0.0 0 13.3 2 
Emesis 3.3 1 0.0 0 6.7 1 
Polyneuropathy 16.7 5 20.0 12 26.7 12 
Ototoxicity 0.0 0 20.0 1 3.3 1 
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 Suppl. Table 1 (online only) 
Specific rules of dose reduction and delay. Rules for myelotoxicity, neurotoxicity, ototoxicity 
and nephrotoxicity were defined prospectively in the trial protocol. ANC = absolute 
neutrophil count; CTC = common toxicity criteria; GFR = glomerular filtration rate; G-CSF = 
granulocyte colony stimulating factor. 
 
Myelotoxixity ANC < 1500/µl AND/OR  
platelets < 100 000/µl 
Delay treatment for one week, repeat 
blood analysis 
 CTC° III 
1000/μl < leukocytes < 2000/μl 
OR 
500/μl < neutrophiles < 1000/μl 
Dose reduction to 75% in the next cycle 
 CTC° IV 
leukocytes < 1000/μl OR 
neutrophiles < 500/μl 
Dose reduction to 50% in the next cycle 
PLUS administration of G-CSF day 5-9 
Neurotoxicity CTC° II Reduction of Vincristine to 1 mg total 
dose 
 CTC° III Termination of Vincristine; if 
improvement to grade II, 1 mg total dose 
Nephrotoxicity GFR > 60 ml/min x 1.73m2 Replace cisplatin by carboplatin 400 
mg/m2 
 GFR < 60 ml/min x 1.73m2  One week treatment break; if no 
improvement: termination of platinum-
based treatment 
Supplementary file Table 1 Click here to download Supplementary file Suppl Tab 1_final
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Ototoxicity 1-3 kHz range reduction of 16-
30 db 
Replace cisplatin by carboplatin 400 
mg/m2 
 4-8 kHz range reduction > 40 db 
 1-3 kHz range reduction > 30 db Termination of platinum – based 
treatment 
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Suppl. Table 2 (online only) 
Imaging response parameters and outcome parameters during the course of treatment and at 
the end of active treatment phase. P-values compare lateral vs. other localization and SSH-
activated tumors vs. non-SHH-activated tumors. N.a. is not applicable. 
 
Characteristic Mean / range  
n / % of total / p-value 
Tumor volume 
 
before treatment for enhancing tumor 
before treatment for non-enhancing 
tumor 
after resection 
after radio-chemotherapy 
 
 
 
14.6 cm³ (range 0.0-37.1)  
25.0 cm³ (range 0.6-38.4) 
 
0.8 cm³ (range 0-9.3) 
0.1 cm³ (range 0-1.6) 
 
MRI response 
 
Complete resection after surgery 
   lateral localization 
   other localizations 
   SHH subgroup 
   other subgroups 
Resection of at least 90% 
Partial resection of any extent 
 
 
 
15 (50.0%) 
63.6% 
36.7% (p = 0.018) 
45.3% 
38.7% (p=0.026) 
4 (13.3%) 
8 (26.6%) 
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Complete response after radio-
chemotherapy 
 
22 (73.3%) 
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Suppl. Table 3 (online only) 
Hematological and non-hematological toxicity Grade 1 & 2 and 3 & 4 in percent (%) of all 
treated patients during concomitant radio-chemotherapy (RCT) and adjuvant chemotherapy 
(cycle 1-8), Number of patients still under treatment are shown in brackets. 
 
 RCT  
(n=30) 
Cycle 
1  
(n=25) 
Cycle 
2  
(n=25) 
Cycle 
3  
(n=21) 
Cycle 
4 
(n=21) 
Cycle 
5 
(n=21) 
Cycle 
6 
(n=19) 
Cycle 
7 
(n=13) 
Cycle 
8 
(n=10) 
Grade 1 & 2          
Leukopenia 53·3 36·0 48·0 42·9 42·9 40·0 42·1 30·8 30·0 
Thrombocytopenia 56·7 0·0 20·0 30·0 26·7 23·3 30·0 13·3 10·0 
Anemia 70·0 64·0 72·0 71·4 76·2 66·7 78·9 69·2 80·0 
Infection 23·3 8·0 0·0 4·8 14·3 9·5 5·3 15·4 10·0 
Nausea 66·7 36·0 20·0 28·6 33·3 14·3 31·6 15·4 10·0 
Emesis 30·0 16·0 4·0 9·5 9·5 4·8 15·8 0·0 0·0 
Polyneuropathy 30·0 32·0 52·0 61·9 66·7 52·4 47·4 53·8 60·0 
Ototoxicity 10·0 20·0 16·0 14·3 19·0 28·6 26·3 23·1 30·0 
Grade 3 & 4          
Leukopenia 36·7 48·0 44·0 47·6 42·9 52·4 31·6 38·5 40·0 
Thrombocytopenia 3·3 12·0 12·0 14·3 23·8 28·6 31·6 30·8 30·0 
Anemia 13·3 8·0 16·0 14·3 9·5 14·3 15·8 15·4 10·0 
Infection 10·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0 
Nausea 6·7 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0 
Emesis 3·3 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0 
Polyneuropathy 16.7 16·0 20·0 4·8 4·8 4·8 0·0 0·0 0·0 
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Ototoxicity 0·0 0·0 0·0 0·0 0·0 0·0 0·0 5·3 0·0 
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Suppl. Table 4 (online only) 
Compliance (calculated as the number of received forms divided by the number of expected 
forms) to health-related quality of life (HRQoL) assessments during the course of treatment 
and at the end of the active treatment phase. *In figure 2a, b, and c, patient numbers are given 
with 22, 21 and 21, as one patient has not answered the respective questions in the 
questionnaires.  
 
 
Moment of evaluation 
 
Number of 
expected HRQoL 
forms 
Number of 
received 
HRQoL forms 
Compliance (%) 
Post-operative 30 24 80 
Post-radiotherapy 30 17 57 
Cycle 1 25 22* 88 
Cycle 2 24 17 71 
Cycle 3 21 16 76 
Cycle 4 20 15 75 
Cycle 5 20 16 80 
Cycle 6 18 12 67 
Cycle 7 12 10 83 
Cycle 8 9 6 67 
End of active treatment 27 18 67 
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Suppl. Table 5 (online only) 
Compliance (calculated as the number of received forms divided by the number of expected 
forms) to health-related quality of life (HRQoL) assessments during the course of treatment 
and at the end of the active treatment phase. *In figure 2a, b, and c, patient numbers are given 
with 22, 21 and 21, as one patient has not answered the respective questions in the 
questionnaires.  
 
 
Moment of evaluation 
 
Number of 
expected HRQoL 
forms 
Number of 
received 
HRQoL forms 
Compliance (%) 
Post-operative 30 24 80 
Post-radiotherapy 30 17 57 
Cycle 1 25 22* 88 
Cycle 2 24 17 71 
Cycle 3 21 16 76 
Cycle 4 20 15 75 
Cycle 5 20 16 80 
Cycle 6 18 12 67 
Cycle 7 12 10 83 
Cycle 8 9 6 67 
End of active treatment 27 18 67 
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Suppl. Table 6 (online only) 
Correlation analysis. Molecular subtypes were correlated to histology, molecular subtype to 
localization, and MRI localization to molecular subtype. Histology was available in all 30 
patients, molecular subtype in 29 patients. MRI localization was not available in 4 patients 
due to missing source data. Significance was calculated for SHH vs. other molecular subtypes 
and for lateral vs. other localizations. 
 
Characteristic n (% of total; p-value) 
 
Genetic and histological entity (n=29) 
 
SHH-activated 
   with CMB histology 
   with DNMB histology 
   with MBEN histology 
 
WNT-activated 
   with CMB histology 
   with LCA histology 
 
Non-WNT/Non-SHH (Group 4) 
   with CMB histology 
   with LCA histology 
 
 
 
20 (66·7%) 
30·0% 
70·0% 
0·0% 
 
4 (13·3%) 
100·0% 
0·0% 
 
5 (16·%) 
100·0% 
0·0% 
Genetic entity (n=29) and MRI  
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localization (n=26) 
 
SHH-activated 
   lateral localization 
   other localization 
 
WNT-activated  
   lateral localization 
   other localization 
 
Non-WNT/Non-SHH (Group 4) 
   lateral localization 
   other localization 
 
Not available 
 
p = 0·01 
 
20 (66·7%) 
50·0% 
50·0% 
 
4 (13·3%) 
0·0% 
100·0% 
 
5 (16·7%) 
20·0% 
80·0% 
 
1 (3·3%) 
 
MRI localization (n=26) and genetic 
entity (n=29)  
 
Lateral/hemispheric localization 
…SHH-activated 
…other subgroup 
 
Non-lateral localization 
   SHH-activated 
 
p = 0·040 
 
11 (36·7%) 
90·9% 
9·1% 
 
15 (50·0%) 
52·6% 
 3 
   other subgroup 
 
Not available 
 
47·4% 
 
4 (13·3%) 
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Supplementary Table and Figure Legends 
 
Suppl. Figure 1 (online only) 
CONSORT statement flow diagram. 
 
Suppl. Figure 2 (online only) 
Treatment delay during adjuvant chemotherapy. Treatment delay is shown in average in days and for 
individual cycles of chemotherapy. Treatment was delayed for 10 days in average, and 70 days in 
maximum (A). Amount of dose de-escalation for each substance. Vincristine was stopped early on in 
a high number of patients, whereas lumustine and cisplatin were first de-escalated, and typically 
stopped later. Data show numbers of patients with 0% of dose (corresponding to termination of the 
respective substance), and 50%, 75%, and full dose per substance per cycle (B). D = day. 
 
Suppl. Figure 3 (online only) 
Health-related quality of life (other than main categories). Scores over time for the exploratory 
scales/items, including the number of patients with HRQoL data at each time point. 
 
Suppl. Figure 4 (online only) 
Lexical and semantic verbal fluency. Scores over time after resection (time point 1 = TP1), after 
radio-chemotherapy (time point 2 = TP2), and after adjuvant therapy (time point 3 = TP3) are shown. 
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Suppl. Table 1 (online only) 
Specific rules for dose de-escalation and delay. Rules for myelotoxicity, neurotoxicity, 
ototoxicity and nephrotoxicity were defined prospectively in the trial protocol. ANC = 
absolute neutrophil count; CTC = common toxicity criteria; GFR = glomerular filtration rate; 
G-CSF = granulocyte colony stimulating factor. 
 
Suppl. Table 2 (online only) 
Imaging response parameters and outcome parameters during the course of treatment and at 
the end of active treatment phase. P-values compare lateral vs. other localization and SSH 
activated tumors vs. non-SHH-activated tumors. N.a. is not applicable. 
 
Suppl. Table 3 (online only) 
Hematological and non-hematological toxicity Grade 1 & 2 and 3 & 4 in percent (%) of all 
treated patients during concomitant radio-chemotherapy (RCT) and adjuvant chemotherapy 
(cycle 1-8), Number of patients still under treatment are shown in brackets. 
 
Suppl. Table 4 (online only) 
Compliance (calculated as the number of received forms divided by the number of expected 
forms) to health-related quality of life (HRQoL) assessments during the course of treatment 
and at the end of the active treatment phase. *In figure 2a, b, and c, patient numbers are given 
with 22, 21 and 21, as one patient has not answered the respective questions in the 
questionnaires.  
 
Suppl. Table 5 (online only) 
Postoperative Health-Related Quality of Life (HRQoL) scores for the preselected scales and 
the exploratory scales/items (scales: higher scores mean better functioning, items: higher 
scores mean more problems), separately for medulloblastoma patients, the general population 
and newly diagnosed glioblastoma patients. 
 
Suppl. Table 6 (online only) 
Correlation analysis. Molecular subtypes were correlated to histology, molecular subtype to 
localization, and MRI localization to molecular subtype. Histology was available in all 30 
patients, molecular subtype in 29 patients. MRI localization was not available in 4 patients 
due to missing source data. Significance was calculated for SHH vs. other molecular subtypes 
and for lateral vs. other localizations. 
 
